Hinova Pharmaceuticals Management
Management criteria checks 3/4
Hinova Pharmaceuticals' CEO is Yuanwei Chen, appointed in Sep 2020, has a tenure of 4.33 years. directly owns 13.26% of the company’s shares, worth CN¥359.90M. The average tenure of the management team and the board of directors is 4.3 years and 4.3 years respectively.
Key information
Yuanwei Chen
Chief executive officer
CN¥3.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.3yrs |
| CEO ownership | 13.3% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
CEO
Yuanwei Chen (61 yo)
4.3yrs
Tenure
CN¥3,177,400
Compensation
Dr. Yuanwei Chen is Chairman of the Board and General Manager of Hinova Pharmaceuticals Inc. since September 21, 2020. Dr. Chen has been General Manager of China Gateway Pharma Products (ChengDu) and Vice...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & General Manager | 4.3yrs | CN¥3.18m | 13.26% CN¥ 359.9m | |
| VP of Operations | 4.3yrs | CN¥1.41m | no data | |
| CTO & Director | 4.3yrs | CN¥2.40m | 1.58% CN¥ 42.9m | |
| Accounting Supervisor | no data | no data | no data | |
| Executive Vice President of Commercial | 1.2yrs | no data | no data |
4.3yrs
Average Tenure
61yo
Average Age
Experienced Management: 688302's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & General Manager | 4.3yrs | CN¥3.18m | 13.26% CN¥ 359.9m | |
| VP of Operations | 1.3yrs | CN¥1.41m | no data | |
| CTO & Director | 4.3yrs | CN¥2.40m | 1.58% CN¥ 42.9m | |
| Director | 4.3yrs | CN¥745.20k | 3.87% CN¥ 105.0m | |
| Independent Director | 4.3yrs | CN¥180.00k | no data | |
| Supervisor | 1.3yrs | no data | no data |
4.3yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 688302's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 21:45 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hinova Pharmaceuticals Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tielin Chen | Topsperity Securities |
| Xinming Zhou | Topsperity Securities |